The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

Authors :: Ghayas C. Issa
Ibrahim Aldoss
John F. DiPersio
Branko Cuglievan
Richard M. Stone
Martha L. Arellano
Michael J. Thirman
Manish R. Patel
David Dickens
Shalini Shenoy
Neerav Shukla
Galit Rosen
Rebecca G. Bagley
Michael L. Meyers
Kate Madigan
Peter Ordentlich
Yu Gu
Steven Smith
Gerard M. McGeehan
Eytan Stein
Source :: Blood. 140:150-152
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools